Table 2.
Novel T2D susceptibility loci achieving genome-wide significance (p<5×10−8), identified through trans-ethnic “discovery” GWAS meta-analysis of 26,488 cases and 83,964 controls of European, East Asian, South Asian, and Mexican and Mexican American ancestry, with follow-up in a “validation” meta-analysis of an additional 21,491 cases and 55,647 controls of European ancestry, genotyped with the Metabochip.
| Locus | Lead SNP | Chr | Build 36 position (bp) | Allelesa | Trans-ethnic “discovery” meta-analysis | European ancestry “validation” meta-analysis | Combined meta-analysis | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk | Other | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | ||||
| TMEM154 | rs6813195 | 4 | 153,739,925 | C | T | 1.08 (1.05–1.11) | 4.2×10−9 | 1.08 (1.05–1.11) | 2.0×10−6 | 1.08 (1.06–1.10) | 4.1×10−14 |
| SSR1/RREB1 | rs9505118 | 6 | 7,235,436 | A | G | 1.06 (1.04–1.09) | 1.9×10−6 | 1.06 (1.03–1.09) | 1.7×10−4 | 1.06 (1.04–1.08) | 1.4×10−9 |
| FAF1 | rs17106184 | 1 | 50,682,573 | G | A | 1.11 (1.07–1.16) | 1.9×10−6 | 1.09 (1.04–1.15) | 4.8×10−4 | 1.10 (1.07–1.14) | 4.1×10−9 |
| POU5F1/TCF19 | rs3130501 | 6 | 31,244,432 | G | A | 1.07 (1.04–1.10) | 1.5×10−6 | 1.06 (1.03–1.10) | 7.0×10−4 | 1.07 (1.04–1.09) | 4.2×10−9 |
| LPP | rs6808574 | 3 | 189,223,217 | C | T | 1.08 (1.04–1.11) | 4.3×10−6 | 1.06 (1.03–1.09) | 2.6×10−4 | 1.07 (1.04–1.09) | 5.8×10−9 |
| ARL15 | rs702634 | 5 | 53,307,177 | A | G | 1.08 (1.05–1.11) | 3.4×10−7 | 1.05 (1.02–1.08) | 2.1×10−3 | 1.06 (1.04–1.09) | 6.9×10−9 |
| MPHOSPH9 | rs4275659 | 12 | 122,013,881 | C | T | 1.06 (1.03–1.09) | 5.5×10−6 | 1.06 (1.02–1.09) | 4.4×10−4 | 1.06 (1.04–1.08) | 9.5×10−9 |
Chr: chromosome. OR: odds-ratio. CI: confidence interval.
a
Alleles are aligned to the forward strand of NCBI Build 36.